Reductive activation of conformationally-constrained, anticancer drug delivery systems

Medicinal Chemistry Research

Volumn 8, Issue 7-8, 1998, Pages 444-456

  Gharat, Laxmikant ^a   Visser, Petra ^a   Brummelhuis, Mathijn ^a   Guiles, Ronald ^a   Chikhale, Prashant ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIMETHYLBENZOQUINONE; HYDROQUININE; MELPHALAN; SODIUM BOROHYDRIDE; UNCLASSIFIED DRUG;

CANCER INHIBITION; CONFERENCE PAPER; CYCLIC POTENTIOMETRY; DRUG CONFORMATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; ELECTROCHEMICAL ANALYSIS; HUMAN; HUMAN CELL; HYPOXIC CELL; OXIDATION REDUCTION REACTION; TARGET CELL;

EID: 0032447565     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Adair, C.G., Burns, D.T., Crockard, A.D., Desai, Z.R. and Harriott, M. (1984). Modified extraction and chromatography for the measurement of plasma melphalan by ion-pair high-performance liquid chromatography. J. Chromat., 336, 429-433.
2. Amsberry, K.L. and Borchardt, R.T. (1991). Amine prodrugs which utilize hydroxy amide lactonization. I. A potential redox-sensitive amide prodrug. Pharm. Res., 8, 323-330.
3. Amsberry K.L., Gerstenberger and Borchardt, R.T. (1991). Amine prodrugs which utilize hydroxy amide lactonization. II. A potential esterase-sensitive amide prodrug. Pharm. Res., 8, 455-461.
4. Alwell G.J., Sykes, B.M., O'Connor, C.J., and Denny, W.A. (1994). Relationships between structure and kinetics of cyclization of 2-aminoaryl amides: Potential prodrugs of cyclization activated aromatic mustards. J. Med. Chem., 37, 371-380.
5. Beall, H.D., Mulcahy, R.T., Siegel, D., Traver, R.D., Gibson, N.W., and Ross, D. (1994). Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorase. Cancer Res., 54, 3196-3201.
6. Bruice T.C. and Marquardt, F. (1962). Hydroxyl group catalysis. IV. The mecahnism of intramolecular participation of aliphatic hydroxyl group in amide hydrolysis. Org. Biol. Chem., 84, 365-370.
7. Cain, B.F. (1976). 2-Acyloxymethylbenzoic acids. Novel amine protective functions providing amides with the lability of esters. J. Org. Chem., 41, 2029-2031.
8. Carpino, L.A., Triolo, S.A., and Berglund, R.A. (1989). Reductive lactonization of strategically methylated quinone propionic acid esters and amides. J. Org. Chem., 54, 3303-3310.
9. Caswell, M. and Schmir, G.L. (1980). Formation and hydrolysis of lactones of phenolic acids. J. Am. Chem. Soc., 102, 4815-4821.
10. Chambers, J.Q. (1974). Electrochemistry of quinones. In The chemistry of quinonoid compounds, Patai, S. (ed.), Interscience, New York, pp 737-791.
11. Chang, S.Y., Alberts, D.S., Farquhar, D., Melnick, L.R., Walson, P.D., and Salmon, S.E. (1978). Hydrolysis and protein binding of melphalan. J. Pharm. Sci., 67, 682-684.
12. Chikhale, P., Gharat, L., Visser, P., Brummelhuis, M., Guiles, R., and Borchardt, R. (1997). Tumor targeted prodrugs: Redox-activation of conformationally-constrained, bioreductive melphalan prodrugs. Proc. Amer. Assoc. Cancer Res., 32, 432-433.
13. Chikhale, P.J., Nakagami, H., and Borchardt, R. T. (1995). A novel esterase-sensitive polymeric prodrug system for amine containing drugs. Pharm. Res., 12, S-245.
14. Chikhale, P.J., Kawamura, Y., Nerurkar, M., Shah, P.K., Amsberry, K.L., and Borchardt, R.T. (1995a). Intestinal transport and metabolism of novel enkephalin prodrugs. Pharm. Res., 12, S-305.
15. Denny, W.A. and Wilson, W.R. (1986). Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J. Med. Chem. 29, 879-887.
16. Flora, K.P., Smith, S.L., and Cradock, J.C. (1979). Application of a simple high-performance liquid Chromatographic method for the determination of melphalan in the presence of its hydrolysis prodructs. J. Chromat., 177, 91-97.
17. Fry, A.J. (1988). Techniques for investigation of electrode reactions. In Synthetic Organic Electrochemistry, 2nd edition, Wiley-Interscience, New York, pp 48-65.
18. Furner, R.L. and Brown, R.K. (1980). L-phenylalanine mustard (L-PAM): The First 25 years. [review]. Cancer Treat. Rep. 64, 559-
19. Furner, R.L., Mellett, L.B., Brown, R.K., and Duncan, G. (1976). A method for the measurement of 1-phenylalanine mustard in the mouse and dogs by high-pressure liquid chromatography. Drug Metabol. Disp., 4, 577-583.
20. Greene, T.W. and Wuts, P.G.M. (1991). Protection of the carboxyl group. In Protective groups in organic synthesis, 2nd edition, Wiley-Interscience, New York, pp 231-234.
21. Gutierrez, P.L. (1989). Mechanism(s) of bioreductive activation. The example of diaziquinone (AZQ). Free Rad. Biol. Med. 6, 405-445.
22. Hay, M.P., Wilson, W.R., Moselen, J.W., Palmer, B.D. and Denny, W.A. (1994). Hypoxia-selective antitumor agents. 8. Bis (nitroimidazolyl) alkane carboxamides: A new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitizers. J. Med. Chem., 37, 381-391.
23. 5 reductase. Cancer Res., 53, 4907-4912.
24. Hopkin, K. (1996). Cancer in focus. J. NIH Res., 9, 37-41.
25. Jain, R.K. (1996). Delivery of molecular medicine to solid tumors. Science, 271, 1079-1080.
26. Kennedy, K.A., Rockwell, S. and Sartorelli, A.C. (1980). Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res., 40, 2356-2360.
27. Kennedy, K.A, Teicher, B.A., Rockwell, S. and Sartorelli, A.C. (1980). The hypoxic tumor cell, a target for selective cancer chemotherapy. Biochem. Pharmacol., 29, 1-8.
28. Lin, A.J., Lillis, B.J. and Sartorelli, A.C. (1975) Potential bioreductive alkylaying agents. 5. Antineoplastic activity of quinoline-5,8-diones, napthazarins and naphthoquinones. J. Med. Chem., 18, 917-921.
29. Lin, A.J. and Sartorelli, A.C. (1976). Potential bioreductive alkylating agents. VI. Determination of the relationship between oxidation-reduction potential and antineoplastic activity. Biochem. Pharmacol., 25, 206-207.
30. Nicolaou, M.G., Yuan, C.S. and Borchardt R.T. (1996). Phosphate prodrugs for amines utilizing a fast intramolecular hydroxy amide lactonization. J. Org. Chem., 61, 8636-8641.
31. Olive, P.L., Vikse, C.M. and Durand, R.E. (1994). Hypoxic fractions measured in murine tumors and normal tissue using the comet assay. Int. J. Rad. Oncol. Biol. Phys. 23, 487-491.
32. Pan, S., Andrews, P.A. and Glover, C.J. (1984). Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by the NADPH-cytochrome P-450 reductase and xanthine oxidase. J. Biol. Chem., 259, 959-966.
33. Pauletti, G.M., Gangwar, S., Wang, B. and Borchardt, R.T. (1997). Esterase-sensitive cyclic prodrugs of peptides: Evaluation of the phenylpropionic acid promoiety in a model hexapeptide. Pharm. Res., 14, 11-17.
34. Plumb, J.A., Gerritsen, M., Milroy, R., Thompson, P., and Workman, P. (1994). Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys., 29, 295-299.
35. Rachele, J.R. (1963). The methyl esterification of amino acids with 2,2-dimethoxypropane and aqueous hydrogen chloride. J. Org. Chem., 28, 2898.
36. Rockwell, S. (1992). Use of hypoxia-directed drugs in the therapy of solid tumors. Seminars in Oncol., 19, 29-40.
37. Sartorelli, A.C. (1988). Therapeutic attack of hypoxic cells of solid tumors, presidential address. Cancer. Res., 48, 775-778.
38. Sartorelli, A., Hodnick, W.F., Beicourt, M.F., Tomasz, M., Haffty, B., Fischer, J.J., and Rockwell, S. (1994). Mitomycin C: A prototype bioreductive agent. Oncol. Res., 6, 501-508.
39. R possessing in vivo antitumor activity. Bioorg. Med. Chem. Lett., 3, 1761-1766.
40. Wang, B., Wang, W., Zhang, H., Shan, D. and Smith, T.D. (1996). Bioorg. Med. Chem. Lett., 6, 2823-2826.
41. Workman, P. (1992). Keynote address: Bioreductive mechanisms. Int. J. Radiat.. Oncol. Biol. Phys., 22, 631-637.